FDA Inspection 1131717 — Paul R. Harmatz, M.D.
The FDA completed an inspection of Paul R. Harmatz, M.D. on Oct 16, 2020 in Oakland, CA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Oct 16, 2020
- Fiscal Year
- 2021
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Oakland, CA (United States)
Additional Details
Clinical Investigator (CI)